Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms

Abstract Background: Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression. Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed. Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01). Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.

Download Full-text

Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms

10.21203/rs.2.14452/v2 ◽

2019 ◽

Author(s):

Anna Santaella ◽

H. Bea Kuiperij ◽

Anouke van Rumund ◽

Rianne A.J. Esselink ◽

Alain J. van Gool ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Growth Factor ◽

Biomarker Discovery ◽

Response To Treatment ◽

Csf Biomarkers ◽

Vascular Parkinsonism ◽

Epidermal Growth ◽

Atypical Parkinsonisms ◽

Proximity Extension Assay

Abstract Background: Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression. Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed. Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01). Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.

Download Full-text

Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms

10.21203/rs.2.14452/v4 ◽

2020 ◽

Author(s):

Anna Santaella ◽

H. Bea Kuiperij ◽

Anouke van Rumund ◽

Rianne A.J. Esselink ◽

Alain J. van Gool ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Growth Factor ◽

Biomarker Discovery ◽

Response To Treatment ◽

Csf Biomarkers ◽

Vascular Parkinsonism ◽

Epidermal Growth ◽

Atypical Parkinsonisms ◽

Proximity Extension Assay

Abstract Background: Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression. Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed. Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01). Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.

Download Full-text

Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms

10.21203/rs.2.14452/v1 ◽

2019 ◽

Author(s):

Anna Santaella ◽

H. Bea Kuiperij ◽

Anouke van Rumund ◽

Rianne A.J. Esselink ◽

Alain J. van Gool ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Growth Factor ◽

Biomarker Discovery ◽

Response To Treatment ◽

Csf Biomarkers ◽

Diagnostic Biomarkers ◽

Epidermal Growth ◽

Atypical Parkinsonisms ◽

Proximity Extension Assay

Abstract Background : Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify inflammatory biomarkers in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology to identify diagnostic biomarkers of PD and APD and to study possible correlations of biomarkers with disease progression. Methods : CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 46; multiple system atrophy (MSA) , n = 15; vascular parkinsonism (VaP) , n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed. Results : Concentrations of CCL28 were elevated in PD compared to controls (p < 0.05). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER) , were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.600; p < 0.01). Conclusions : PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.

Download Full-text

Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson’s Disease and Atypical Parkinsonisms

Frontiers in Neuroscience ◽

10.3389/fnins.2020.00624 ◽

2020 ◽

Vol 14 ◽

Author(s):

Samanta Mazzetti ◽

Mara De Leonardis ◽

Gloria Gagliardi ◽

Alessandra Maria Calogero ◽

Milo Jarno Basellini ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Protein Aggregates ◽

Atypical Parkinsonisms

Download Full-text

Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

Movement Disorders ◽

10.1002/mds.26907 ◽

2017 ◽

Vol 32 (2) ◽

pp. 181-192 ◽

Cited By ~ 42

Author(s):

Antonio P. Strafella ◽

Nicolaas I. Bohnen ◽

Joel S. Perlmutter ◽

David Eidelberg ◽

Nicola Pavese ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Molecular Imaging ◽

Atypical Parkinsonisms

Download Full-text

ELEVATED SALIVARY DJ-1 IN PARKINSON'S DISEASE IS ASSOCIATED WITH ALTERED SALIVARY SECRETION

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp-2015-312379.23 ◽

2015 ◽

Vol 86 (11) ◽

pp. e4.111-e4

Author(s):

Joseph Masters ◽

Alaistair Noyce ◽

Gavin Giovannoni ◽

Tom Warner ◽

Gordon Proctor

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Total Protein ◽

Protein Concentration ◽

Rating Scale ◽

Biomarker Discovery ◽

Periodic Acid ◽

Salivary Flow ◽

Total Protein Concentration ◽

Periodic Acid Schiff

AimTo investigate the composition of saliva in patients with Parkinson's disease (PD).MethodsSaliva was collected from 16 patients with PD and 22 age-matched controls. Salivary DJ-1 concentrations were measured with quantitative immunoblotting; total protein concentration with a BCA assay; amylase with an amylase activity assay; and mucin concentrations with periodic-acid Schiff stained SDS gels.ResultsSalivary flow rate was not significantly different between patients and controls. Patient saliva showed increases in DJ-1 concentration (0.84 vs 0.42 µg/ml, p=0.001) and total protein concentration (8.4 vs 5.0 mg/ml, p=0.001). In patients, adjusted DJ-1 levels correlated with disease severity measured with the Unified Parkinson's Disease Rating Scale (p=0.019). Concentrations of amylase, but not mucins, were elevated in the saliva of patients (0.127 vs 0.061 units/ml, p<0.001) and correlated positively with both total protein (p<0.001) and DJ-1 concentration (p<0.013).ConclusionsThis preliminary study suggests that the saliva of patients with PD is different in composition to that of controls, which supports the notion that saliva may be a good candidate for biomarker discovery in PD. Altered protein secretion may be a manifestation of autonomic dysfunction in PD.

Download Full-text